Physician
Hamza Abrar Mughal
Department of Plastic Surgery, Lillebaelt Hospital, Vejle
| Projekt styring | ||
| Projekt status | Open | |
| Data indsamlingsdatoer | ||
| Start | 01.09.2023 | |
| Slut | 31.08.2024 | |
The clinical relevance of routine histological examination of mastectomy scars during breast reconstruction and breast implant replacement - a retrospective study
Short summary
Women with breast cancer may require a mastectomy as part of their cancer treatment. Many of these women undergo breast reconstruction surgery. It is common practice to submit mastectomy scars for routine histology at the time of breast reconstruction and breast implant replacement to ensure that there is no cancer recurrence. In this study, we review all mastectomy scars submitted for routine histological examination during breast reconstruction and implant replacement over a five-year period.
Rationale
It is debatable whether routine submission of mastectomy scars for histological examination during breast reconstruction and breast implant replacement or removal is necessary. Further investigation is needed, as excessive examination could cause unnecessary concern and anxiety for some patients. Additionally, it's important to consider that this practice results in an increased workload for surgeons, nurses, and pathologists. If routine histology of mastectomy scars could be avoided without compromising on patient care, it would lead to better utilisation of healthcare resources.
Description of the cohort
Eligible patients are patients who have undergone mastectomy followed by one of the following procedures at Lillebaelt Hospital, Vejle, Denmark over a five-year period (from 1 January 2018 to 31 December 2022): - Breast reconstruction (implant-based or autologous). - Breast implant replacement or removal after implant-based breast reconstruction. Eligible patients must have one of the following diagnoses verified by a biopsy: - Invasive ductal carcinoma (IDC) - Invasive lobular carcinoma (ILC) - Other invasive carcinoma - Ductal carcinoma in situ (DCIS) - Lobular carcinoma in situ (LCIS) Patients with clinical signs of breast cancer recurrence at the time of breast reconstruction or breast implant replacement or removal will be excluded.
Data and biological material
Data from the electronic health record and histology report of mastectomy scars. The following parameters will be documented: cancer histology, cancer stage, receptor status, type of breast reconstruction, age at the time of surgery, time between mastectomy and scar sampling, number of previous breast implant replacement surgeries if any, and mastectomy scar histology report.